Takeda Pharmaceutical Company Limited (TYO:4502)
4,218.00
+57.00 (1.37%)
Feb 21, 2025, 3:30 PM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.14T JPY in the quarter ending December 31, 2024, with 2.96% growth. This brings the company's revenue in the last twelve months to 4.58T, up 9.83% year-over-year. In the fiscal year ending March 31, 2024, Takeda Pharmaceutical Company had annual revenue of 4.26T with 5.87% growth.
Revenue (ttm)
4,579.02B
Revenue Growth
+9.83%
P/S Ratio
1.45
Revenue / Employee
92.92M
Employees
49,281
Market Cap
6,686.35B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
Mar 31, 2020 | 3,291.19B | 1,193.96B | 56.93% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,170.61B |
Daiichi Sankyo Company | 1,795.99B |
HOYA Corporation | 837.44B |
Terumo | 1,011.15B |
Otsuka Holdings | 2,329.86B |
Astellas Pharma | 1,867.63B |
Olympus | 993.33B |
Shionogi & | 456.87B |
Takeda Pharmaceutical Company News
- 22 days ago - Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued - Seeking Alpha
- 22 days ago - Takeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Suffolk Celebrates Topping off for a Game-Changing New Takeda Facility in Kendall Square Where Science, Art and Community Will Converge - Business Wire
- 23 days ago - Takeda Pharmaceutical Names U.S. Head Julie Kim as Next CEO - The Wall Street Journal
- 23 days ago - Earnings Scheduled For January 30, 2025 - Benzinga
- 23 days ago - Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 - Business Wire
- 23 days ago - Takeda Pharmaceutical Co Ltd (TAK) Reports Strong Q3 FY2024 Results and Announces Share Buyback - GuruFocus
- 23 days ago - Takeda Pharmaceutical Non-GAAP EPS of ¥443.00, revenue of ¥3528.2B; raises FY outlook - Seeking Alpha